This page shows the latest Doptelet news and features for those working in and with pharma, biotech and healthcare.
Earlier this month, NICE also published final draft guidance recommending the use of Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia who are scheduled to undergo an invasive procedure. ... Doptelet has a list price of £640 or £960
The results from the late-stage trial of Doptelet in CIT are expected to read out in the first half of 2020. ... However, Dova has dubbed Doptelet as a second-generation TRA, and says its has fewer liver-related side effects than its rival.
Dova Pharma’s Doptelet (avatrombopag) for the treatment of severe thrombocytopenia. Conditional marketing authorisation for Sanofi’s PD-1 checkpoint inhibitor Libtayo (cemiplimab), for advanced cutaneous squamous cell carcinoma.
Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... starting a pivotal trial of Doptelet in chemotherapy induced
Among the biggest biopharma news today is the FDA’s approval of Dova’s Doptelet to treat thrombocytopenia in adult patients with chronic liver disease – although turbulence in biotech stocks saw
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...